116 related articles for article (PubMed ID: 37806848)
1. TuBG1 promotes hepatocellular carcinoma via ATR/P53-apoptosis and cycling pathways.
Zhang Y; Wang ZZ; Han AQ; Yang MY; Zhu LX; Pan FM; Wang Y
Hepatobiliary Pancreat Dis Int; 2024 Apr; 23(2):195-209. PubMed ID: 37806848
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of TUBG1 expression promotes hepatocellular carcinoma development.
Wang ZJ; Dai ZZ; Hu MZ; Liu JN; Liang H; Shen MM; Zhu SJ; Sheng HJ; Gao J; Huang AL; Tang KF
Med Oncol; 2023 Feb; 40(3):96. PubMed ID: 36792863
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
[TBL] [Abstract][Full Text] [Related]
4. Upregulated TUBG1 expression is correlated with poor prognosis in hepatocellular carcinoma.
Zhang K; Yu M; Liu H; Hui Z; Yang N; Bi X; Sun L; Lin R; Lü G
PeerJ; 2022; 10():e14415. PubMed ID: 36523478
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
6. Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest.
Li QZ; Chen YY; Liu QP; Feng ZH; Zhang L; Zhang H
Phytomedicine; 2024 Apr; 126():155177. PubMed ID: 38412667
[TBL] [Abstract][Full Text] [Related]
7. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
8. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
Tian F; Cai D
Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
[TBL] [Abstract][Full Text] [Related]
9. EXOSC10 is a novel hepatocellular carcinoma prognostic biomarker: a comprehensive bioinformatics analysis and experiment verification.
Meng ZY; Fan YC; Zhang CS; Zhang LL; Wu T; Nong MY; Wang T; Chen C; Jiang LH
PeerJ; 2023; 11():e15860. PubMed ID: 37701829
[TBL] [Abstract][Full Text] [Related]
10. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
11. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
Zhang YX; Kong CZ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842
[TBL] [Abstract][Full Text] [Related]
12. 1,25(OH)
Huang J; Yang G; Huang Y; Zhang S
Biochimie; 2018 Mar; 146():28-34. PubMed ID: 29158005
[TBL] [Abstract][Full Text] [Related]
13. Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3.
Zhang G; Zeng X; Zhang R; Liu J; Zhang W; Zhao Y; Zhang X; Wu Z; Tan Y; Wu Y; Du B
Phytomedicine; 2016 Nov; 23(12):1329-1336. PubMed ID: 27765352
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-Dependent Kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using integrated bioinformatic analysis.
Zhang JN; Wei F; Lei LH; Yang Y; Yang Y; Zhou WP
Bioengineered; 2021 Dec; 12(2):11728-11739. PubMed ID: 34784846
[TBL] [Abstract][Full Text] [Related]
15. Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels.
Tucker CA; Kapanen AI; Chikh G; Hoffman BG; Kyle AH; Wilson IM; Masin D; Gascoyne RD; Bally M; Klasa RJ
Mol Cancer Ther; 2008 Apr; 7(4):749-58. PubMed ID: 18375822
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of tumor suppressor p33(ING1b) and its synergy with p53 gene in hepatocellular carcinoma.
Zhu Z; Lin J; Qu JH; Feitelson MA; Ni CR; Li FM; Zhu MH
World J Gastroenterol; 2005 Apr; 11(13):1903-9. PubMed ID: 15800978
[TBL] [Abstract][Full Text] [Related]
17. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
18. SKA3 Promotes tumor growth by regulating CDK2/P53 phosphorylation in hepatocellular carcinoma.
Hou Y; Wang Z; Huang S; Sun C; Zhao J; Shi J; Li Z; Wang Z; He X; Tam NL; Wu L
Cell Death Dis; 2019 Dec; 10(12):929. PubMed ID: 31804459
[TBL] [Abstract][Full Text] [Related]
19. CBL0137 administration suppresses human hepatocellular carcinoma cells proliferation and induces apoptosis associated with multiple cell death related proteins.
Albahde MAH; Zhang P; Chen H; Wang W
Neoplasma; 2020 May; 67(3):547-556. PubMed ID: 32202904
[TBL] [Abstract][Full Text] [Related]
20. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis.
Qi R; An H; Yu Y; Zhang M; Liu S; Xu H; Guo Z; Cheng T; Cao X
Cancer Res; 2003 Dec; 63(23):8323-9. PubMed ID: 14678992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
